Compound for treatment of respiratory condition or disease
AssigneeBiota Scientific Management Pty Ltd.
InventorsJohn Nicholas Lambert, Jane Ryan, Janet Marie Wilson
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment, alleviation, prevention or reduction of symptoms or exacerbations of asthma or chronic obstructive pulmonary disease (COPD), of which reduced lung function is typically symptomatic.
Claims25
A method for treating or alleviating symptoms of asthma comprising administering 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof to a subject in need thereof.
A method for treating or alleviating symptoms of COPD comprising administering 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof to a subject in need thereof.
A method for reducing the incidence of exacerbations or preventing exacerbations of asthma comprising administering 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof to a subject at risk thereof.
A method for reducing the incidence of exacerbations or preventing exacerbations of COPD comprising administering 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzo[d]isoxazole or a pharmaceutically acceptable salts thereof to a subject at risk thereof.
A pharmaceutical combination comprising 3-ethoxy-6-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzo[d]isoxazole or a pharmaceutically acceptable salt thereof and at least one asthma medication.
Dependencies are inferred from the claim text.